(Q73168740)
Statements
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention (English)
E J Topol
1 reference
A M Lincoff
K Kottke-Marchant
S R Steinhubl
D J Moliterno
M L Rosenthal
N K Godfrey